Skip Nav Destination
Issues
1 April 2004
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Editorials
Reviews
The Biology Behind
Featured Articles
Clinical Trials
Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
David P. Ryan; Joseph P. Eder, Jr.; Thomas Puchlaski; Michael V. Seiden; Thomas J. Lynch; Charles S. Fuchs; Philip C. Amrein; Darrell Sonnichsen; Jeffrey G. Supko; Jeffrey W. Clark
Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging
Joseph G. Rajendran; David A. Mankoff; Finbarr O’Sullivan; Lanell M. Peterson; David L. Schwartz; Ernest U. Conrad; Alexander M. Spence; Mark Muzi; D. Greg Farwell; Kenneth A. Krohn
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response
William Larry Gluck; Deborah Hurst; Alan Yuen; Alexandra M. Levine; Mark A. Dayton; Jon P. Gockerman; Jennifer Lucas; Kimberly Denis-Mize; Barbara Tong; Dawn Navis; Anita Difrancesco; Sandra Milan; Susan E. Wilson; Maurice Wolin
Molecular Oncology, Markers, Clinical Correlates
Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)
Marlene A. Dressman; Rachel Malinowski; Lee Anne McLean; Insa Gathmann; Renaud Capdeville; Martee Hensley; IRIS (International Randomized Study of Interferon-α versus STI571) Study Group; Mihael H. Polymeropoulos
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
Elton R. Kisanga; Jennifer Gjerde; Aliana Guerrieri-Gonzaga; Francesca Pigatto; Adriana Pesci-Feltri; Chris Robertson; Davide Serrano; Giuseppe Pelosi; Andrea Decensi; Ernst A. Lien
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Defective Expression of Transforming Growth Factor β Receptor Type II Is Associated with CpG Methylated Promoter in Primary Non-Small Cell Lung Cancer
Hong-Tao Zhang; Xiao-Feng Chen; Ming-Hua Wang; Jiu-Cun Wang; Qing-Yuan Qi; Rong-Mei Zhang; Wei-Qing Xu; Qing-Yan Fei; Fei Wang; Qi-Qun Cheng; Feng Chen; Cheng-Song Zhu; Shi-Heng Tao; Zewei Luo
Real-Time Gap Ligase Chain Reaction: A Rapid Semiquantitative Assay for Detecting p53 Mutation at Low Levels in Surgical Margins and Lymph Nodes from Resected Lung and Head and Neck Tumors
Susan V. Harden; David C. Thomas; Nicole Benoit; Khalid Minhas; William H. Westra; Joseph A. Califano; Wayne Koch; David Sidransky
Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers
Jens Koopmann; Phillip Buckhaults; David A. Brown; Marianna L. Zahurak; Norihiro Sato; Noriyoshi Fukushima; Lori J. Sokoll; Daniel W. Chan; Charles J. Yeo; Ralph H. Hruban; Samuel N. Breit; Kenneth W. Kinzler; Bert Vogelstein; Michael Goggins
Endothelin-1-, Endothelin-A-, and Endothelin-B-Receptor Expression Is Correlated with Vascular Endothelial Growth Factor Expression and Angiogenesis in Breast Cancer
Pia Wülfing; Christian Kersting; Joke Tio; Rudolph-Josef Fischer; Christian Wülfing; Christopher Poremba; Raihanatou Diallo; Werner Böcker; Ludwig Kiesel
UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated with Hepatocellular Carcinoma in Japanese Patients with Hepatitis C Virus Infection
Yue Wang; Naoya Kato; Yujin Hoshida; Motoyuki Otsuka; Hiroyoshi Taniguchi; Masaru Moriyama; Shuichiro Shiina; Takao Kawabe; Yoichi M. Ito; Masao Omata
Expression of Nuclear Factor-κB and IκBα Proteins in Prostatic Adenocarcinomas: Correlation of Nuclear Factor-κB Immunoreactivity with Disease Recurrence
Jeffrey S. Ross; Bhaskar V. S. Kallakury; Christine E. Sheehan; Hugh A. G. Fisher; Ronald P. Kaufman, Jr.; Prabhjot Kaur; Karen Gray; Bradley Stringer
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers
Sunil R. Lakhani; Sanjiv Manek; Frederique Penault-Llorca; Adrienne Flanagan; Laurent Arnout; Samantha Merrett; Lesley McGuffog; Dawn Steele; Peter Devilee; Jan G. M. Klijn; Hanne Meijers-Heijboer; Paolo Radice; Silvana Pilotti; Heli Nevanlinna; Ralf Butzow; Hagay Sobol; Jocylyne Jacquemier; Dominique Stoppa Lyonet; Susan L. Neuhausen; Barbara Weber; Teresa Wagner; Robert Winqvist; Yves-Jean Bignon; Franco Monti; Fernando Schmitt; Gilbert Lenoir; Susanne Seitz; Ute Hamman; Paul Pharoah; Geoff Lane; Bruce Ponder; D. Timothy Bishop; Douglas F. Easton
Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer
Supaporn Suwiwat; Carmela Ricciardelli; Raija Tammi; Markku Tammi; Paivi Auvinen; Veli-Matti Kosma; Richard G. LeBaron; Wendy A. Raymond; Wayne D. Tilley; David J. Horsfall
Experimental Therapeutics, Preclinical Pharmacology
HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice
David Finkle; Zhi Ricky Quan; Vida Asghari; Jessica Kloss; Nazli Ghaboosi; Elaine Mai; Wai Lee Wong; Philip Hollingshead; Ralph Schwall; Hartmut Koeppen; Sharon Erickson
Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
Corinna Warburton; Wieslawa H. Dragowska; Karen Gelmon; Stephen Chia; Hong Yan; Dana Masin; Tetyana Denyssevych; Anne E. Wallis; Marcel B. Bally
Specific Chemopreventive Agents Trigger Proteasomal Degradation of G1 Cyclins: Implications for Combination Therapy
Konstantin H. Dragnev; Ian Pitha-Rowe; Yan Ma; W. Jeffrey Petty; David Sekula; Bryan Murphy; Mara Rendi; Nanjoo Suh; Neil B. Desai; Michael B. Sporn; Sarah J. Freemantle; Ethan Dmitrovsky
Letter to the Editor
Correction
Advertisement
